Transgene strengthens its scientific committee with two immunotherapy experts.

Transgene, a biotechnology company specializing in cancer immunotherapies, has announced the addition of two prominent new members to its scientific advisory board. Antoine Italiano and Ignacio Melero, both internationally recognized for their expertise in cancer immunotherapy, will make a significant contribution to Transgene's product development.

Antoine Italiano, a world-renowned oncologist, is head of the Department of Medicine at the Bergonié Institute. He has led numerous clinical trials focusing on immuno-oncology and targeted therapies. Ignacio Melero, meanwhile, is a professor of immunology at the University of Navarra and has conducted significant research on monoclonal antibodies and cell immunotherapy.

This dual appointment aims to strengthen Transgene's therapeutic innovation, particularly in the development of its myvac® platform and viral vector-based cancer vaccine candidates.